| Literature DB >> 35464538 |
Mahmoud A Kiblawi1, Kashif Hafeez2, Shahed K Lami3, Omar A Al Teneiji4, Abdullah N Al Mubarak5, Thaer K Swaid1, Sundos A Ahmed1, Roaa S Alabiri6, Ruba S Alabiri6.
Abstract
INTRODUCTION: Thyroid cancer is the most prevalent endocrine cancer worldwide. It is the second most common type of cancer among United Arab Emirates (UAE) women and ranks as the sixth most common type of cancer overall among the UAE population. There are limited studies in the UAE related to thyroid malignancy. This study aimed to determine the pattern of thyroid malignancy among the UAE population and its associated characteristics, with more emphasis on patients categorized as Bethesda III by cytopathology, and furthermore, to determine the significance of advanced diagnostic methods in the assessment of thyroid nodules.Entities:
Keywords: bethesda; goitre; thyroid malignancy; thyroid nodule; ultrasound score
Year: 2022 PMID: 35464538 PMCID: PMC9015698 DOI: 10.7759/cureus.23321
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Demographics of the total study population
| Total study population demographics | Total patients (n=1072) | Thyroid malignancy (n=174) |
| Gender | Male n=182 (17%) | Male n=39 (22%) |
| Female n=890 (83%) | Female n=135 (78%) | |
| Nationality | UAE national n=561 (52%) | UAE national n=67 (39%) |
| Non-national n=511 (58%) | Non-national n=107 (61%) | |
| Age (years) | (<30) n=131 (12%) | (<30) n=30 (17%) |
| (30-39) n=295 (28%) | (30-39) n=60 (34.5%) | |
| (40-49) n=301 (28%) | (40-49) n=46 (26%) | |
| (50-59) n=173 (16%) | (50-59) n=25 (14%) | |
| (≥60) n=172 (16%) | (≥60) n=13 (7.5%) |
Figure 1The percentage of thyroid malignancy among UAE population
Bethesda classification of the total study population
| Bethesda classification | |||
| Category | Total FNA (n=422) | Malignancy (n=174) | Non-malignancy post-surgery (n=39) |
| I | n=25 (6%) | n=4 (2%) | n=1 (2.5%) |
| II | n=138 (33%) | n=14 (8%) | n=12 (31%) |
| III | n=140 (33%) | n=30 (17%) | n=16 (41%) |
| IV | n=19 (4.5%) | n=19 (11%) | n=0 |
| V | n=39 (9%) | n=37 (21%) | n=1 (2.5%) |
| VI | n=61 (14.5%) | n=57 (33%) | n=1 (2.5%) |
| FNA result absent | n=13 (7.5%) | n=8 (20.5%) | |
Figure 2Types of thyroid malignancy from the total study population
Figure 3Thyroid malignancy patients characteristics - total study population
Demographics of Bethesda III patients
| Bethesda III demographics | Total patients (n=140) | Thyroid malignancy (n=30) |
| Gender | Male n=25 (18%) | Male n=5 (17%) |
| Female n=115 (82%) | Female n=25 (83%) | |
| Nationality | UAE national n=72 (51%) | UAE national n=15 (50%) |
| Non-national n=68 (49%) | Non-national n=15 (50%) | |
| Age (years) | (<30) n=12 (8.5%) | (<30) n=5 (17%) |
| (30–39) n=34 (24%) | 30–39) n=9 (30%) | |
| (40–49) n=47 (33.5%) | (40–49) n=7 (23%) | |
| (50–59) n=18 (13%) | (50–59) n=5 (17%) | |
| (≥60) n=29 (21%) | (≥60) n=4 (13%) | |
| Total patients who underwent thyroid surgery | Surgery (n=46) | |
| Type of thyroid malignancy | Papillary n=26 (87%) | |
| Follicular n=4 (13%) |
Ultrasound grading in the Bethesda III population
| Bethesda III ultrasound scoring system – “U” and “TI-RADS” | |||
| Classification | Grading | Total Bethesda III (n=140) | Malignancy (n=30) |
| “U” + “TI-RADS” | Grade 1 | n=0 | n=0 |
| Grade 2 | n=8 (6%) | n=1 (3%) | |
| Grade 3 | n=55 (39%) | n=10 (33%) | |
| Grade 4 | n=39 (28%) | n=10 (33%) | |
| Grade 5 | n=11 (8%) | n=1 (3%) | |
| Unclassified | n=27 (19%) | n=8 (27%) | |
Figure 4Thyroid malignancy patients characteristics - Bethesda III